terlipressin
Jump to navigation
Jump to search
Introduction
FDA approved in USA
Indications
Contraindications
Dosage
Adverse effects
- associated with increased incidence of cardiovascular events
Mechanism of action
- vasopressin analogue
- reverses splanchnic vasodilation associated with hepatic cirrhosis, thus increases effective arterial volume and renal perfusion
More general terms
References
- ↑ 1.0 1.1 Sanyal AJ et al for the Terlipressin Study Group. A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology. 2008 May;134(5):1360-8. Epub 2008 Feb 13. PMID: https://www.ncbi.nlm.nih.gov/pubmed/18471513
Martin-Llahi M et al for the TAHRS Investigators. Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. Gastroenterology. 2008 May;134(5):1352-9. Epub 2008 Feb 14. PMID: https://www.ncbi.nlm.nih.gov/pubmed/18471512 - ↑ FDA News & Events for human Drugs. Sept 14, 2022 FDA approves treatment to improve kidney function in adults with hepatorenal syndrome. https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-treatment-improve-kidney-function-adults-hepatorenal-syndrome
- ↑ 3.0 3.1 Pitre T, Kiflen M, Helmeczi W The Comparative Effectiveness of Vasoactive Treatments for Hepatorenal Syndrome: A Systematic Review and Network Meta-Analysis. PMID: https://www.ncbi.nlm.nih.gov/pubmed/35777925 https://journals.lww.com/ccmjournal/Fulltext/2022/10000/The_Comparative_Effectiveness_of_Vasoactive.1.aspx
- ↑ 4.0 4.1 4.2 4.3 4.4 Garcia-Tsao G et al. AGA clinical practice update on the use of vasoactive drugs and intravenous albumin in cirrhosis: Expert review. Gastroenterology 2024 Jan; 166:202. PMID: https://www.ncbi.nlm.nih.gov/pubmed/37978969 https://www.gastrojournal.org/article/S0016-5085(23)05143-0/fulltext